Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
68,578,543
-
Total 13F shares
-
31,635,340
-
Share change
-
+5,220,005
-
Total reported value
-
$1,033,195,545
-
Price per share
-
$32.69
-
Number of holders
-
65
-
Value change
-
+$169,604,096
-
Number of buys
-
43
-
Number of sells
-
13
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) as of Q3 2020
As of 30 Sep 2020,
Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,635,340 shares.
The largest 10 holders included
VIKING GLOBAL INVESTORS LP, Matrix Capital Management Company, LP, FMR LLC, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, Redmile Group, LLC, CITADEL ADVISORS LLC, PRIMECAP MANAGEMENT CO/CA/, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, and PERCEPTIVE ADVISORS LLC.
This page lists
65
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.